Want to see SVA full AI Analyst Report?
Sinovac Biotech (SVA) Risk Analysis
Risk Overview Q4, 2025
Risk Change Over Time
- Share Price & Shareholder Rights - Risk 1Our common shares may be prohibited from trading in the United States under the HFCAA in the future if the PCAOB is unable to inspect or investigate completely registered public accounting firms headquartered in the Chinese mainland and Hong Kong. The delisting of, or prohibition on trading, our common shares, or the threat of their being delisted or prohibited from being traded, may materially and adversely affect the value of your investment.
Pursuant to the HFCAA, if the SEC determines that we have filed audit reports issued by a registered public accounting firm that has not been subject to inspections by the PCAOB because of a position taken by an authority in the foreign jurisdiction for two consecutive years, the SEC will prohibit our common shares from being traded on a national securities exchange or in the over-the-counter trading market in the United States. On December 16, 2021, the PCAOB issued a report to notify the SEC of its determination that the PCAOB was unable to inspect or investigate completely registered public accounting firms headquartered in the Chinese mainland and Hong Kong. On December 15, 2022, the PCAOB removed the Chinese mainland and Hong Kong from the list of jurisdictions where it is unable to inspect or investigate completely registered public accounting firms. Each year, the PCAOB will determine whether it can inspect and investigate completely audit firms in the Chinese mainland and Hong Kong, among other jurisdictions. If the PCAOB determines in the future that it no longer has full access to inspect and investigate completely accounting firms in the Chinese mainland and Hong Kong and we use an accounting firm headquartered in one of these jurisdictions to issue an audit report on our financial statements filed with the SEC, we would be identified as a Commission-Identified Issuer following the filing of the annual report on Form 20-F for the relevant fiscal year. In accordance with the HFCAA, our securities would be prohibited from being traded on a national securities exchange or in the over-the-counter trading market in the United States if we are identified as a Commission-Identified Issuer for two consecutive years in the future. A prohibition on trading in the United States would substantially impair your ability to sell or purchase our common shares when you wish to do so, and the risk and uncertainty associated with such a prohibition would have a negative impact on the price of our common shares. Also, such a prohibition would significantly affect our ability to raise capital on terms acceptable to us, or at all, which would have a material adverse effect on our business, financial condition, and prospects.
- Share Price & Shareholder Rights - Risk 2The PCAOB had historically been unable to inspect our auditor, and such inability deprived our investors of the benefits of PCAOB inspections.
Our auditor, the independent registered public accounting firm that issues the audit report included elsewhere in this annual report, as an auditor of companies that are traded publicly in the United States and a firm registered with the PCAOB, is subject to laws in the United States pursuant to which the PCAOB conducts regular inspections to assess its compliance with applicable professional standards. Since our auditor is located in China, a jurisdiction where the PCAOB was historically unable to conduct inspections and investigations completely before 2022, the PCAOB had not been able to conduct inspections of our auditor. The inability of the PCAOB to conduct inspections of auditors in China made it more difficult to evaluate the effectiveness of our independent registered public accounting firm's audit procedures or quality control procedures as compared to auditors outside of China that are subject to PCAOB inspections. On December 15, 2022, the PCAOB issued a report that vacated its December 16, 2021 determination and removed the Chinese mainland and Hong Kong from the list of jurisdictions where it is unable to inspect or investigate completely registered public accounting firms. However, if the PCAOB determines in the future that it no longer has full access to inspect and investigate completely accounting firms in the Chinese mainland and Hong Kong, and we use an accounting firm headquartered in one of these jurisdictions to issue an audit report on our financial statements filed with the SEC, we and investors in our common shares would be deprived of the benefits of such PCAOB inspections, which could cause investors and potential investors to lose confidence in our audit procedures and reported financial information and the quality of our financial statements.
- Share Price & Shareholder Rights - Risk 3Because Sinovac Antigua is incorporated under Antigua and Barbuda law, substantially all of our operations, property and assets are located in China and all of our major shareholders, directors and officers and substantially all of their assets are located outside of the United States, you may have difficulty protecting your interests as a shareholder under U.S. law in a court in the United States.
Sinovac Antigua is incorporated in Antigua and Barbuda. Sinovac Antigua's corporate affairs are governed by its Articles of Incorporation and By-laws and by the International Business Corporations Act and common law of Antigua and Barbuda. The rights of shareholders to take legal action against Sinovac Antigua's directors, officers and us, actions by minority shareholders and the fiduciary responsibilities of Sinovac Antigua's directors to Sinovac Antigua are to a large extent governed by the International Business Corporations Act and common law of Antigua and Barbuda. The International Business Corporations Act was modelled on Canadian company law. The common law of Antigua and Barbuda is derived from comparatively limited judicial precedent in Antigua and Barbuda as well as from English common law, which has persuasive, but not binding, authority on a court in Antigua and Barbuda. The rights of Sinovac Antigua's shareholders and the fiduciary responsibilities of Sinovac Antigua's directors under Antigua and Barbuda law are not as clearly established as they would be under statutes or judicial precedents in the United States. Among other things, Antigua and Barbuda has a less developed body of securities laws than the United States and provides significantly less protection to investors. Further, Antigua and Barbuda's body of securities law and the experience of its courts in addressing corporate and securities law issues commonly encountered by public companies are likely less developed than those of some of the other jurisdictions where publicly traded China-based companies are incorporated, such as the Cayman Islands. It may be difficult or impossible for you to bring an action against us or against Sinovac Antigua's directors or officers in Antigua and Barbuda or to enforce your rights under U.S. securities laws or otherwise. Even if you are successful in bringing an action of this kind, you may be unable to enforce a judgment against our assets or the assets of Sinovac Antigua's directors and officers under the laws of Antigua and Barbuda. It is uncertain whether Antigua and Barbuda courts would enforce judgments of United States courts obtained in actions against us or Sinovac Antigua's directors or officers that are predicated upon the civil liability provisions of the Securities Act, or in original actions brought against us or such persons predicated upon the Securities Act. There is no treaty in effect between the United States and Antigua and Barbuda providing for such enforcement, and Antigua and Barbuda courts may decline to enforce judgments of United States courts on certain grounds. In addition, Antigua and Barbuda corporations may not have standing to initiate a shareholder derivative action before the federal courts of the United States. PRC courts may recognize and enforce foreign judgments in accordance with the PRC Civil Procedures Law based either on treaties between the PRC and the country where the judgment is made or on reciprocity between jurisdictions. In the absence of such treaties or reciprocity arrangements, recognition and enforcement of a foreign judgment in the PRC may need to be resolved through diplomatic channels. The PRC does not have any treaties or other arrangements with the United States or Antigua and Barbuda that provide for the reciprocal recognition and enforcement of foreign judgments. As a result, it is generally difficult to enforce in the PRC a judgment rendered by a U.S. or Antigua and Barbuda court. As a result of the foregoing, and because substantially all of our property, assets and operations are located in China and all of our major shareholders, directors and officers and substantially all of their assets are located outside of the United States, you may have difficulty protecting your interests as a shareholder through legal action against us, our officers, directors or major shareholders.
- Share Price & Shareholder Rights - Risk 4Sinovac Antigua could issue additional common shares or preferred shares, which could have the effect of diluting existing shareholders and impairing their voting and other rights.
Sinovac Antigua's Articles of Incorporation authorize the issuance of up to 100,000,000 common shares and 50,000,000 preferred shares. The preferred shares may be issued with such designations, rights, privileges, restrictions and conditions as may be determined from time to time by Sinovac Antigua's board of directors. Sinovac Antigua's board is empowered, without shareholder approval, to issue additional common shares or preferred shares. The issuance of additional common shares could dilute the interest of existing shareholders. In addition, preferred shares may be issued with dividend, liquidation, conversion, voting, or other rights that could further dilute the interest of, or impair the voting and other rights of, Sinovac Antigua's existing shareholders. The issuance of such additional common shares or preferred shares could also be used as a method of discouraging, delaying, or preventing a change in control.
- Share Price & Shareholder Rights - Risk 5The interests of the minority shareholders of Sinovac Beijing, Sinovac LS and Sinovac Dalian may diverge from our own, which may adversely affect our ability to manage these subsidiaries.
We hold majority equity interests in each of Sinovac Beijing, Sinovac LS and Sinovac Dalian. If our interests diverge from those of our minority shareholders, they may exercise their rights under the relevant articles of association, shareholders' agreements or joint venture contracts of such subsidiaries and the relevant PRC laws to protect their own interests, which may substantially differ from ours. As a result, our ability to manage these subsidiaries, and their respective subsidiaries and affiliates, may be adversely affected, which in turn may materially and adversely affect our business, financial condition and results of operations. Sinovac Beijing is a Sino-foreign equity joint venture in which we own a 73.09% equity interest. In 2018, Mr. Aihua Pan, acting as the representative of the then minority shareholder of Sinovac Beijing, Sinobioway Bio-medicine Co., Ltd. (formerly named Xiamen Bioway Group Co., Ltd., "Sinobioway Medicine"), took a series of disruptive actions against Sinovac Beijing, including purporting to terminate the employment of senior managers without board approval, forcibly entering Sinovac Beijing's corporate offices and cutting power to production facilities, which resulted in the destruction of products and bacterial seed stocks, the temporary suspension of production, and the postponement of an NMPA inspection necessary for PPSV23 production approval. In September 2020, the Beijing No. 4 Intermediate People's Court held Sinobioway Medicine and Mr. Aihua Pan liable for torts and breaches of shareholders' fiduciary duty and awarded Sinovac Beijing damages of RMB15.4 million, which was upheld on appeal by the Higher People's Court of Beijing Municipality in October 2022, which further ruled that Shandong Sinobioway Biomedicine, as the sole shareholder of Sinobioway Medicine, is jointly and severally liable for all relevant obligations of Sinobioway Medicine. In addition, Sinobioway Medicine filed complaints seeking to dissolve and liquidate Sinovac Beijing and claiming that Sinovac LS infringed the legitimate rights of Sinovac Beijing in connection with the research and development of CoronaVac, both of which were subsequently voluntarily withdrawn. In July 2023, following a settlement under the supervision of Zhangdian District Court, Shandong Sinobioway Biomedicine replaced Sinobioway Medicine as the minority shareholder of Sinovac Beijing, and the legal representative and chairman of the board of directors of Sinovac Beijing was changed from Mr. Aihua Pan to Mr. Weidong Yin. These and other actions taken by the former minority shareholder of Sinovac Beijing and its representatives have materially and adversely affected, and any similar actions in the future may continue to materially and adversely affect, our business, financial condition and results of operations. We cannot assure you that Shandong Sinobioway Biomedicine, the current minority shareholder of Sinovac Beijing, will cooperate with us in handling matters related to the operations of Sinovac Beijing in the future. As of the date of this annual report, Dalian Jin Gang Group, the minority shareholder of Sinovac Dalian, has been cooperating with us with respect to the business of Sinovac Dalian, and the minority shareholders of Sinovac LS have been aligned with us with respect to the business of Sinovac LS. However, we cannot assure you that these minority shareholders will continue to cooperate with us in the future.
- Share Price & Shareholder Rights - Risk 6Our business, governance and reputation could be negatively affected by shareholder disputes, litigation or actions of shareholders or others.
Sinovac Antigua and certain of its subsidiaries, directors and officers are involved in a number of legal proceedings across various jurisdictions. For detailed information, see "Item 8. Financial Information - Legal and Administrative Proceedings." We cannot predict the outcome of these proceedings or any other actions initiated by shareholders or other parties. Nor can we predict how such actions may affect Sinovac Antigua's share price, which could experience significant volatility during the pendency of these proceedings and following their resolution. The preparation and defense of these matters have caused us to incur substantial costs, and we expect such costs to continue until the litigation concludes. Preparing for and managing litigation is also time-consuming and may disrupt our operations and divert the attention of management and key employees from the execution of our strategic plan. Shareholder disputes may also affect, or be perceived to affect, our corporate governance, our ability to make major strategic decisions, and the confidence of governmental authorities, customers, business partners, employees, investors and other stakeholders. Negative publicity relating to such disputes may harm our reputation and could have a material adverse effect on our business, financial condition, results of operations and prospects. Although the litigation arising from our annual general meeting of shareholders held on February 6, 2018 has been concluded, there is ongoing litigation concerning the 2018 PIPE Shares and the special shareholders' meeting held on July 8, 2025. In addition, there is currently a restraint placed upon Sinovac Antigua from holding a shareholder meeting while the proceedings relating to the special shareholders' meeting (the "SSM Proceedings") are pending. As a result of the earlier litigation concerning the 2018 annual general meeting and the current restraint imposed in connection with the SSM Proceedings, Sinovac Antigua has not been able to hold an annual meeting of shareholders since February 2018, and its shareholders will not have the opportunity to vote in an election of Sinovac Antigua's directors for an indeterminate amount of time. The disputes with respect to the PIPE Shares could have a material adverse effect on the results of our operations and our financial condition. An amount equal to the aggregate cash that would otherwise be payable under the 2025 Dividend in respect of the 2018 PIPE Shares has been set aside and retained in an escrow account of Sinovac Antigua. This amount will remain in escrow pending the final resolution of the ongoing litigation and arbitration proceedings with respect to the PIPE Shares in Antigua and Hong Kong. The timing and outcome of these proceedings are uncertain.
- Accounting & Financial Operations - Risk 7We rely on dividends paid by our Chinese Mainland Subsidiaries for our cash needs. If they are unable to pay us sufficient dividends due to statutory, regulatory or contractual restrictions on their ability to distribute dividends to us, our various cash needs may not be met.
Sinovac Antigua is a holding company, and we rely in part on dividends paid by our Chinese Mainland Subsidiaries, including our majority-owned subsidiaries Sinovac Beijing, Sinovac Dalian and Sinovac LS, and our wholly owned subsidiaries Sinovac Biomed and Sinovac Services, for our cash needs, including the funds necessary to pay dividends and other cash distributions to Sinovac Antigua's shareholders, service any debt we may incur, and pay our operating expenses. If any of our Chinese Mainland Subsidiaries incur debt on their own behalf in the future, the instruments governing such debt may restrict their ability to pay dividends or make other distributions to us. The payment of dividends in the PRC is subject to significant limitations. Regulations in the PRC currently permit payment of dividends by our Chinese Mainland Subsidiaries only out of accumulated profits as determined in accordance with PRC accounting standards and regulations. In accordance with PRC laws and regulations, Sinovac Beijing, Sinovac Dalian, Sinovac LS, Sinovac Biomed and Sinovac Services are each required to set aside at least 10% of their respective after-tax profits each year to contribute to a statutory reserve fund until the accumulated balance of each such fund reaches 50% of the registered capital of each such company. These subsidiaries may also set aside, at the discretion of their respective boards of directors, a portion of their annual after-tax profits to employee welfare and bonus funds. These allocations, together with the statutory reserve fund contributions described above, reduce the amount of funds available for distribution as dividends to us. Revenues of our Chinese Mainland Subsidiaries are primarily denominated in renminbi, which is not freely convertible into other currencies. As a result, any restriction on currency exchange may limit the ability of our Chinese Mainland Subsidiaries to use their renminbi-denominated revenues to pay dividends to us. Additionally, there can be no assurance that the PRC government will not impose additional regulatory requirements or restrictions governing the convertibility of renminbi into foreign currencies or the remittance of dividends and other distributions by PRC entities to their overseas shareholders, including in response to foreign exchange policy adjustments, changes in global economic conditions, or other considerations. The regulatory framework governing cross-border dividend payments remains subject to change, and we cannot predict whether or when the PRC government may introduce further limitations on dividend distributions to overseas entities. If such additional restrictions are imposed, or if we are otherwise unable to access sufficient foreign currencies to meet our needs, we may be unable to pay dividends to our shareholders in foreign currencies. Any limitation on the ability of our Chinese Mainland Subsidiaries to pay dividends or make other distributions to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business.
- Debt & Financing - Risk 8We may need additional capital to upgrade or construct our production facilities, to continue development of our product pipeline, and to market existing and future products on a large scale. We cannot guarantee that we will find adequate sources of capital in the future.
In the future, we may need to raise additional funds to finance equipment expenditures, to acquire intellectual property, to upgrade existing manufacturing facilities and develop GMP-compliant production facilities for pipeline products, to continue the development and commercialization of our product candidates, and to fund other corporate purposes. As of December 31, 2025, we had approximately $1,156.4 million in cash and cash equivalents and restricted cash. We may undertake significant future financings in order to: - upgrade existing manufacturing facilities and develop GMP-compliant production facilities for pipeline products;- proceed with the research and development of other vaccine products, including clinical trials of new products;- commercialize our products, including the marketing and distribution of new and existing products;- seek and obtain regulatory approvals;- develop or acquire, directly or indirectly through the acquisition of companies, other product candidates, technologies, or companies;- protect our intellectual property; and - finance general, administrative, and research activities that are not related to specific products under development. In the past, we funded most of our research and development and other expenditures through government grants, working capital, bank loans and proceeds from private placements and public offerings of Sinovac Antigua's common shares. We may need to raise additional funds in the future because our current operating and capital resources may be insufficient to meet future requirements. Sinovac Antigua is authorized to issue 100,000,000 common shares, of which 71,860,702 are issued and outstanding as of the date of this annual report. To increase the number of authorized common shares, we must amend Sinovac Antigua's Articles of Incorporation and By-laws, which requires (i) a majority of common shares to be present for a quorum, and (ii) the affirmative vote of two-thirds of common shares present and voting at the general meeting. We cannot assure you that Sinovac Antigua will be able to collect sufficient affirmative votes to amend its Articles of Incorporation and By-laws. If we fail to increase the number of authorized common shares of Sinovac Antigua, we may have insufficient common shares available for future issuances of equity securities to meet our capital needs. If we raise additional funds by issuing equity securities, it will result in further dilution to our existing shareholders. The dilutive impact may be exacerbated if the shares are sold when the market price is low, as shares issued in equity financing transactions will normally be sold at a discount to the current market price. Any additional equity securities issued may also provide for rights, preferences, or privileges senior or otherwise preferential to those of holders of our existing common shares. Unforeseen problems, including materially negative developments relating to, among other things, disease developments, product sales, new product rollouts, clinical trials, research and development programs, our strategic relationships, our intellectual property, litigation, regulatory changes in our industry, the Chinese market generally, or general economic conditions, could interfere with our ability to raise additional funds or materially and adversely affect the terms upon which such funding is available. If we raise additional funds by issuing debt securities, these debt securities would have rights, preferences, and privileges senior to those of holders of Sinovac Antigua's common shares, and the terms of the debt securities issued could impose significant restrictions on our operations. If we raise additional funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to certain of our technologies, marketing territories, product candidates, or products that we would otherwise seek to develop or commercialize ourselves, or be required to grant licenses on terms that are not favorable to us. In the past, our Chinese Mainland Subsidiaries have received various types of grants from the PRC government to finance their research and development and facility investment for their vaccine products. They may not receive additional grants in the future. As described above, the actions of the Shareholder Group leading up to and at the 2017 AGM resulted in uncertainties as to the future direction of our company and the composition of Sinovac Antigua's board of directors. As a result of these uncertainties, we do not know whether additional financing will be available to us on commercially acceptable terms when needed. If adequate funds are not available or are not available on commercially acceptable terms, we may be unable to continue developing our products. In any such event, our ability to bring a product to market and earn revenues could be delayed, and competitors could develop products sooner than we do. As a result, our business, financial condition, and results of operations could be materially and adversely affected. Our capital requirements may also increase due to rising raw material prices, higher labor costs, equipment maintenance and validation costs, depreciation and amortization associated with production facilities and information systems, and compliance costs associated with evolving regulatory requirements. We may not be able to reduce or offset such costs through price increases, cost savings, or productivity improvements, particularly in markets subject to government procurement or intense price competition.
- Corporate Activity and Growth - Risk 9Acquisitions and strategic alliances we undertake may have a material adverse effect on our ability to manage our business and may ultimately prove unsuccessful.
Our growth strategy may involve the acquisition of new production lines, technologies, businesses, products or services, or the formation of strategic alliances in areas in which we do not currently operate. These acquisitions and strategic alliances may require our management to develop expertise in new areas or geographies, manage new business relationships and attract new types of customers. The significant management attention required to pursue and integrate such transactions, and the resulting diversion of management's attention and resources, could have a material adverse effect on our ability to manage our business. We may also experience difficulties integrating acquisitions into our existing business and operations. Future acquisitions and strategic alliances may expose us to potential risks, including risks associated with: - failure or delay in obtaining regulatory approvals for newly acquired product pipelines;- the integration of new operations, services and personnel;- unforeseen or hidden liabilities;- the diversion of resources from our existing businesses and technologies;- our inability to generate sufficient revenue to offset the costs of acquisitions;- potential loss of, or harm to, relationships with employees or customers; and - impairment of intangible assets acquired. Any of the foregoing could significantly disrupt our ability to manage our business and materially and adversely affect our business, financial condition and results of operations. In addition, acquisitions, joint ventures and other strategic alliances in new technologies or therapeutic areas may require us to integrate unfamiliar technologies, personnel, systems, regulatory obligations and business cultures. We may be unable to identify suitable targets, complete transactions on acceptable terms, obtain required regulatory approvals, realize expected synergies or avoid unexpected liabilities.
- Corporate Activity and Growth - Risk 10We may encounter difficulties in managing our organizational structure, operational complexity and evolving business activities, which could adversely affect our business, financial condition and results of operations.
As our business activities, product portfolio, research and development programs, manufacturing operations and regulatory obligations evolve, we may encounter difficulties in managing our organizational structure, operational complexity and business operations. We have developed, and continue to refine, a group-level control and management framework designed to achieve resource synergies and unified management across subsidiaries and business lines. This framework may require ongoing adjustment and integration. A more complex organizational structure may give rise to misalignment between the group and its subsidiaries, delayed, incomplete or distorted information flows, inconsistent implementation of policies, slower decision-making and reduced overall management effectiveness. In addition, expansion into new technologies, products, markets, commercialization models and strategic initiatives may further increase operational, compliance and management complexity, requiring significant management attention and substantial financial and human resources. If we are unable to effectively implement group-level controls, internal reporting systems, delegation of authority, compliance procedures, resource allocation and performance management across our organization, our operational efficiency, internal controls, compliance systems, financial condition and results of operations could be materially and adversely affected.
Risk Highlights Q4, 2025
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 71
- Regulation - Risk 1ChangedBecause our vaccines address conditions that represent significant public health threats, governments may take actions detrimental to our business, including product seizure, compulsory licensing, and additional regulatory burdens, in order to safeguard public access.
In response to a pandemic or the perceived risk of a pandemic, governments around the world may take actions to protect their citizens that could restrict our ability to control the production and export of pandemic vaccines or that could otherwise impose burdensome regulations on our business. Governments might grant compulsory licenses, enabling our competitors to manufacture products protected by our patents or to exploit our proprietary technology. Such actions could be particularly detrimental where we have invested government funding in developing the very products subject to compulsory licensing.
- Regulation - Risk 2ChangedUncertainties exist with respect to how the PRC Vaccine Administration Law and other vaccine-specific regulatory requirements may impact our current operations.
According to the PRC Vaccine Administration Law, the supervision of vaccines covers the entire lifecycle from vaccine development, production and distribution to vaccination. Specialized inspection teams of pharmaceutical professionals are established at the central and provincial levels to conduct supervisory activities. An electronic traceability system has been established to ensure that all information relating to vaccines is trackable throughout the production, distribution and vaccination process. The vaccine tracking system requires that vaccination data, including information relating to the vaccine, its expiry date and date of administration, the administering medical personnel and the recipients, be recorded and retained for at least five years after the vaccine's expiry date. The law imposes stringent penalties on violators, including enhanced criminal liability where a violation constitutes a criminal offence. Since the implementation of the PRC Vaccine Administration Law, the national drug regulatory authority has successively issued a series of supporting regulations and policies covering vaccine research and development, production, distribution, vaccination, traceability and other key aspects, thereby establishing a relatively comprehensive regulatory framework. In 2025, the State Council further promulgated the Regulations for the Implementation of the Drug Administration Law, which systematically refined the key institutional arrangements, operational specifications and reform measures set forth in the PRC Vaccine Administration Law and the PRC Drug Administration Law. The promulgation of the foregoing laws, regulations and supporting documents has rendered the specific requirements for full life-cycle vaccine supervision clearer and more predictable. However, PRC judicial and administrative authorities retain significant discretion in interpreting and implementing statutory provisions and contractual terms. As a result, there remains uncertainty as to how these regulations will be interpreted, amended or implemented by the relevant PRC government authorities, and we cannot assure you that evolving regulatory interpretations or enforcement actions will not have a material adverse effect on our business, financial condition or results of operations. Under the current regulatory framework, we believe we are able to reasonably assess and maintain ongoing compliance with applicable requirements; however, no assurance can be given that future regulatory developments will not necessitate changes to our operations or otherwise adversely affect our business.
- Regulation - Risk 3ChangedWe may not be able to comply with applicable GMP standards, product quality requirements, pharmacopoeia standards, lot release requirements and other regulatory requirements, each of which could have a material adverse effect on our business, financial condition and results of operations.
We are required to comply with applicable GMP regulations, which include, among other things, requirements relating to personnel, premises and equipment, raw materials and products, qualification and validation, document management, production management, quality control and assurance, product distribution and product recalls. Manufacturing facilities must be approved by governmental authorities before they can be used to commercially manufacture our products and are subject to inspection by regulatory agencies. We cannot assure you that we will continue to meet applicable GMP standards, product quality requirements, pharmacopoeia standards, lot release requirements and other regulatory requirements in the future. The hepatitis A vaccine, varicella vaccine and sIPV are all prequalified by the WHO. After prequalification, GMP on-site re-inspections may occur at periodic intervals. If an inspection identifies GMP non-compliance, our prequalification status may be suspended or withdrawn, rendering us ineligible to supply the relevant vaccines to United Nations agencies. Additionally, if our GMP implementation does not comply with local requirements during an overseas registration process, we may be unable to proceed with registration or market access in that country, which could materially reduce our overseas revenues and limit our international growth. The Chinese Pharmacopoeia is regularly revised. When a new version takes effect, marketed vaccines may need to meet updated quality standards, which may require additional studies, process changes, analytical method updates, comparability assessments, variation filings and revalidation. For example, the 2025 Chinese Pharmacopoeia became effective on October 1, 2025. If we fail to complete required studies, implement process changes or obtain required approvals within NMPA deadlines, our products could face restrictions, including suspension of manufacturing or lot release. The newly revised Implementing Regulations of the Drug Administration Law of the PRC, effective May 15, 2026, further reinforce the full lifecycle quality obligations of marketing authorization holders, including requirements to establish an independent quality management department and designate a qualified person for quality. Compliance with these strengthened obligations requires significant enhancements to our internal quality management systems. During the transition period, risks may arise from misinterpretation of new requirements, delayed implementation of necessary changes or gaps in integrating new processes with existing systems. Under the Measures for Lot Release of Biological Products, if a lot release authority identifies a material vaccine quality risk, it must report to the drug regulator, which may refuse or suspend lot release and order corrective actions. Separately, for enterprises with unresolved quality issues or recurring deviations, regulators may increase inspection frequency and conduct unannounced on-site plant inspections. Failure to promptly address manufacturing deviations, maintain complete records or ensure product traceability may trigger heightened scrutiny, lot release delays, production suspension, product recalls, batch rejection, warning letters, suspension of GMP certificates, administrative penalties or reputational damage. If any of our existing or future vaccine candidates obtain marketing approval through a conditional approval pathway, but we fail to complete required confirmatory studies within the prescribed timeframe or the results of such confirmatory studies fail to demonstrate clinical benefit, the relevant drug registration certificate may be revoked. In addition, we rely on third-party suppliers for certain raw materials and components. Quality failures in such input could compromise the safety and efficacy of our finished products, and our ability to seek recourse against such suppliers may be limited. More broadly, any failure to maintain or enhance our quality management system in line with evolving domestic and international standards could impair our ability to access new markets or participate in international procurement tenders.
- Regulation - Risk 4AddedFailure to comply with PRC regulations governing human genetic resources may materially and adversely affect our research and development activities and subject us to significant regulatory and legal consequences.
Our research and development projects, including pre-clinical research and clinical trials, may involve the collection, storage, use, domestic transfer or cross-border provision of human genetic resources or related data. Under the PRC Regulations on the Administration of Human Genetic Resources and their implementing rules, certain activities involving human genetic resources may require prior approval, filing, security review, data backup, reporting or other regulatory compliance procedures. The procedures for human genetic resources approvals or filings may be time-consuming, and projects that fail to complete required procedures may be unable to proceed. If we, our collaborators, clinical trial sites, contract research organizations or other service providers fail to correctly determine whether a project involves human genetic resources, fail to obtain required approvals or complete required filings in a timely manner, or fail to comply with applicable restrictions on data use, domestic transfer, sharing or cross-border provision, we may face suspension or delays of clinical trials and other research activities, rejection of regulatory submissions, administrative penalties including fines and confiscation of illegal gains, reputational harm or other material adverse consequences.
- Regulation - Risk 5AddedHeightened PRC healthcare anti-bribery enforcement and new rules governing medical representatives may increase our compliance obligations, require adjustments to our commercialization arrangements and adversely affect demand for our vaccine products in the Chinese mainland.
Our vaccine products are subject to a highly regulated commercial and promotional environment in the PRC. PRC authorities have continued to strengthen healthcare compliance, anti-corruption and anti-bribery enforcement in the pharmaceutical and vaccine sectors. On April 10, 2026, the Supreme People's Court and the Supreme People's Procuratorate jointly issued the Interpretation on Several Issues Concerning the Application of Law in Handling Criminal Cases of Embezzlement and Bribery (II), effective May 1, 2026, which further clarifies conviction and sentencing standards for bribery-related offenses and identifies bribery in areas including food and drugs and healthcare as circumstances that may trigger enhanced penalties or more severe classification at lower monetary thresholds. In addition, the National Medical Products Administration and several other PRC authorities issued the Administrative Measures for Medical Representatives in 2026, effective August 1, 2026. These measures impose qualification, filing, regional responsibility, compliance undertaking and conduct requirements on medical representatives, prohibit misconduct in academic promotion, including conduct associated with commercial bribery, and hold drug marketing authorization holders responsible for the appointment, authorization, filing and management of medical representatives, including where academic promotion activities are conducted through entrusted professional organizations or other third-party promotion service providers. These developments may require us to further enhance our compliance management of academic promotion, market access and commercialization activities in the Chinese mainland. To the extent we rely on contract sales organizations ("CSOs"), promotion service providers, academic promotion partners or other third-party professional organizations, we may need to update existing arrangements, strengthen qualification review and ongoing monitoring, refine incentive and performance management mechanisms, expand training and audits, enhance controls over interactions with centers for disease control and prevention ("CDCs"), vaccination providers and healthcare professionals, and strengthen expense management and documentation practices. These measures may increase compliance costs, reduce sales and promotion efficiency, delay market access or the compliant dissemination of product information, disrupt third-party relationships, or require us to terminate or replace certain partners or representatives. If our employees, medical representatives, distributors, CSO partners, promotion service providers or other personnel acting on our behalf fail, or are alleged to fail, to comply with applicable anti-bribery, pharmaceutical promotion, medical representative, vaccine administration or healthcare compliance requirements, we may be subject to investigations, administrative penalties, criminal prosecution, disgorgement of gains, restrictions on promotional activities, suspension or revocation of licenses or permits, exclusion from procurement or tendering opportunities, civil claims, reputational harm and other adverse consequences. If we are unable to adapt our commercialization arrangements in a timely and cost-effective manner, or if our third-party partners are unable or unwilling to satisfy the new compliance requirements, our market access, product communication efficiency and demand for our vaccine products in the Chinese mainland, particularly in the private-pay market, may be adversely affected, which could materially and adversely affect our business, financial condition, results of operations and prospects.
- Regulation - Risk 6If we were deemed to be an investment company under the U.S. Investment Company Act of 1940, as amended (the "1940 Act"), applicable restrictions could make it impractical for us to continue our business as contemplated and could have a material adverse effect on our business, financial condition and results of operations.
Under Sections 3(a)(1)(A) and (C) of the 1940 Act, a company generally will be deemed to be an "investment company" for purposes of the 1940 Act if (1) it is, or holds itself out as being, engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities or (2) it engages, or proposes to engage, in the business of investing, reinvesting, owning, holding or trading in securities and it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis. We do not believe that we are an "investment company," as such term is defined in either of those sections of the 1940 Act. Notwithstanding Sections 3(a)(1)(A) and (C) of the 1940 Act, we are a research and development company and intend to conduct our operations in compliance with the safe harbor requirements of Rule 3a-8 of the 1940 Act, such that we will not be deemed an investment company. However, if we were to be deemed an investment company, restrictions imposed by the 1940 Act, including limitations on our capital structure and our ability to transact with affiliates, could make it impractical for us to continue our business as contemplated and could have a material adverse effect on our business, financial condition and results of operations.
- Regulation - Risk 7As a foreign private issuer, we are subject to different U.S. securities laws and NASDAQ listing rules than domestic U.S. issuers.
As a foreign private issuer, we are exempt from certain rules under the Exchange Act, including those prescribing the furnishing and content of quarterly reports and proxy statements. In addition, as an Antigua and Barbuda company listed on the NASDAQ Global Select Market, we are permitted to follow Antigua and Barbuda corporate governance practices in lieu of certain NASDAQ corporate governance standards, subject to certain conditions. Certain corporate governance practices in Antigua and Barbuda may differ significantly from NASDAQ corporate governance standards. As a result, you may not be afforded the same information or protections as would be available to you if you were investing in a domestic U.S. issuer.
- Regulation - Risk 8ChangedThe PRC government's significant oversight and discretion over our business operations could result in a material adverse change in our operations and the value of our common shares.
We conduct our business primarily in China. Our operations in the Chinese mainland are governed by PRC laws and regulations. The PRC government has significant oversight and discretion over the conduct of our business, and may intervene in or influence our operations. The PRC government has recently published new policies that have significantly affected certain industries, and we cannot rule out the possibility that it will in the future release regulations or policies that directly or indirectly affect our industry or require us to seek additional permissions or approvals to continue our operations, which could result in a material adverse effect on our business, financial condition, results of operations, and/or the value of our common shares. Any such action could significantly limit or completely hinder our ability to offer or continue to offer securities to investors, which could cause the value of such securities to significantly decline. As a result, our business and investments in our securities are subject to significant uncertainty due to the PRC government's evolving regulatory environment.
- Regulation - Risk 9ChangedThere may be changes from time to time in the interpretation and application of PRC laws and regulations, and any failure to comply with laws and regulations could have a material adverse effect on our business, results of operations, financial condition and the value of our common shares.
Our operations in the Chinese mainland are governed by PRC laws and regulations. Our Chinese Mainland Subsidiaries are subject to laws and regulations applicable to foreign investment in the Chinese mainland. The PRC legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions under the civil law system may be cited for reference but have limited precedential value. Because the PRC legal system is evolving quickly, many laws, regulations and legal requirements are relatively new, and new laws and regulations may be promulgated or existing laws and regulations, as well as the interpretation and enforcement thereof, may change at any time. In addition, any new PRC laws and regulations, or changes to existing ones, related to foreign investment in the Chinese mainland could affect the business environment and our ability to operate our business in the Chinese mainland. From time to time, we may have to resort to administrative and court proceedings to enforce our legal rights. However, administrative and court proceedings in the Chinese mainland may take a particularly long time, resulting in substantial costs and diversion of resources and management attention. Given that PRC administrative and court authorities retain broad discretion in interpreting and implementing statutory provisions and contractual terms, it may be more difficult to predict the outcome of administrative and court proceedings that we are involved in. These uncertainties may impede our ability to enforce the contracts we have entered into and could materially and adversely affect our business and results of operations.
- Regulation - Risk 10ChangedIt may be difficult for overseas regulators to conduct investigations or collect evidence within the Chinese mainland.
Shareholder claims or regulatory investigations that are common in the United States generally are difficult to pursue as a matter of law or practicality in China. For example, in China, there are legal and other obstacles to providing information needed for regulatory investigations or litigation initiated outside China. Although the authorities in China may establish a regulatory cooperation mechanism with the securities regulatory authorities of another country or region to implement cross-border supervision and administration, such cooperation with the securities regulatory authorities in the United States may not be efficient in the absence of a well-established mutual and practical cooperation mechanism. According to Article 177 of the PRC Securities Law ("Article 177"), no overseas securities regulator is allowed to directly conduct investigation or evidence collection activities within the territory of the PRC. Furthermore, pursuant to the Provisions on Strengthening the Confidentiality and Archives Administration Related to the Overseas Securities Offering and Listing by Domestic Enterprises, which became effective on March 31, 2023, the investigation and evidence collection in relation to the overseas securities offering and listing of PRC companies by overseas securities regulatory authorities and relevant authorities shall be conducted through the cross-border cooperation mechanism for supervision and administration. PRC companies are required to obtain prior consent from CSRC or other relevant PRC authorities before cooperating with overseas securities regulatory authorities in connection with any inspections or investigations, or before providing any relevant documents to such authorities. The inability of an overseas securities regulator to directly conduct investigation or evidence collection activities within China may further increase difficulties faced by you in protecting your interests.
- Regulation - Risk 11PRC regulation of loans and direct investment by offshore holding companies to PRC entities may delay or prevent us from making loans or additional capital contributions to our operating subsidiaries and affiliated entities in the Chinese mainland.
In funding our Chinese Mainland Subsidiaries, we must comply with PRC legal requirements relating to foreign debt registration and to PRC foreign-investment companies' "registered capital" and "total investment" ratio. "Registered capital" refers to the capital contributed to or paid into a PRC foreign-investment company in cash or in kind, and "total investment" refers to the estimated amount of the total capital as required to enable and support the full-scale operation of a PRC foreign-investment company when the company is initially established. The amounts of a PRC foreign-investment company's registered capital and total investment are set forth in the company's articles of association and joint venture contract (in the case of a Sino-foreign joint venture) and approved by the competent government authority in advance. The balance between the required "total investment" and the "registered capital" can be satisfied by borrowings or loans obtained by the company. In other words, such loans cannot exceed the difference between such company's total investment and registered capital. Loans by Sinovac Antigua or Sinovac Hong Kong to Sinovac Beijing, Sinovac LS, Sinovac Dalian, Sinovac Biomed or Sinovac Services cannot exceed the difference between such company's total investment and registered capital. The total investment and registered capital can be adjusted after the establishment of foreign-investment companies with the approval of all the shareholders or unanimous approval of the board of directors. In the case of each of Sinovac Beijing, Sinovac Dalian and Sinovac LS, the approval from their respective minority shareholders is required to increase the amount of total investment. Further, all loans from overseas lenders must be registered with SAFE as foreign debts. We may also decide to finance our Chinese Mainland Subsidiaries by making additional capital contributions. These additional contributions must be approved by the competent government authority and, in the case of each of Sinovac Beijing, Sinovac Dalian and Sinovac LS, the approval from their respective minority shareholders. We cannot assure you that we will be able to obtain these government registrations or approvals, or the approval of the minority shareholders on a timely basis, if at all, with respect to future loans or additional capital contributions by us to our subsidiaries. If we fail to obtain such registrations or approvals, our ability to capitalize our PRC operations would be negatively affected, which could materially and adversely affect the liquidity of our subsidiaries and our ability to expand the business.
- Regulation - Risk 12Any failure to comply with PRC regulations regarding our employee equity incentive plans may subject the PRC plan participants or us to fines and other legal or administrative sanctions.
Pursuant to SAFE Circular 37, PRC residents who participate in share incentive plans of overseas non-publicly listed companies by virtue of their positions as directors, senior management members, or employees of the PRC subsidiaries of such overseas companies may submit applications to SAFE or its local branches for foreign exchange registration with respect to offshore special purpose companies. Sinovac Antigua's directors and our executive officers and other employees who are PRC residents and who have been granted options and restricted shares were required to follow SAFE Circular 37 to apply for foreign exchange registration before our company became an overseas listed company. Since our company became an overseas listed company, its directors, executive officers, and other employees who are PRC residents and who have been granted options have become subject to the Notice on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plans of Overseas Publicly Listed Companies. Under this Notice, PRC-resident employees, directors, supervisors, and other management members who participate in any stock incentive plan of an overseas publicly listed company are required to register with SAFE through a domestic qualified agent, which may be a PRC subsidiary of such overseas listed company, and to complete certain other procedures. Failure to complete SAFE registrations may subject them to fines and other legal or administrative sanctions and may also limit the ability to make payments under our equity incentive plans or receive dividends or sales proceeds related thereto, our ability to contribute additional capital to our wholly-owned subsidiaries in China, and may limit such subsidiaries' ability to distribute dividends to us. We also face regulatory uncertainties that could restrict our ability to adopt additional equity incentive plans for Sinovac Antigua's directors and our employees under PRC law. In addition, the State Administration of Taxation has issued circulars concerning employee share options and restricted shares. Under these circulars, employees working in the PRC who exercise share options, or whose restricted shares or restricted share units ("RSUs") vest, will be subject to PRC individual income tax. The PRC subsidiaries of an overseas listed company are obligated to file documents related to employee share options or restricted shares with the relevant tax authorities and to withhold individual income taxes of those employees in respect of their share options, restricted shares, or RSUs. If the employees fail to pay, or the PRC subsidiaries fail to withhold, their income taxes according to relevant laws, rules, and regulations, the PRC subsidiaries may face sanctions imposed by the tax authorities or other PRC government authorities.
- Regulation - Risk 13ChangedPRC regulations relating to investments in offshore companies by PRC residents may subject our PRC-resident beneficial owners or our Chinese Mainland Subsidiaries to liability or penalties, limit our ability to inject capital into our Chinese Mainland Subsidiaries or limit our Chinese Mainland Subsidiaries' ability to increase their registered capital, receive capital contributions, or distribute profits.
The Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents' Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles ("SAFE Circular 37"), which replaced the former circular commonly known as "SAFE Circular 75", originally required PRC residents to register with the local branches of SAFE (such registration is now processed by local banks pursuant to the Notice on Further Simplifying and Improving Policies for the Foreign Exchange Administration of Direct Investment) in connection with their direct establishment or indirect control of an offshore entity, for the purpose of overseas investment and financing, with such PRC residents' legally owned assets or equity interests in domestic enterprises or offshore assets or interests. Such offshore entity is referred to in SAFE Circular 37 as a "special purpose vehicle." SAFE Circular 37 further requires amendment to the registration in the event of any significant changes with respect to the special purpose vehicle, such as increase or decrease of capital contributed by PRC residents, share transfer or exchange, merger, division, or other material events. In the event that a PRC resident holding interests in a special purpose vehicle fails to fulfill the required foreign exchange registration, the PRC subsidiaries of that special purpose vehicle may be prohibited from making profit distributions to the offshore parent and from carrying out subsequent cross-border foreign exchange activities, and the special purpose vehicle may be restricted in its ability to contribute additional capital into its PRC subsidiary. Failure to comply with the various foreign exchange registration requirements described above could result in liability under PRC law for evasion of foreign exchange controls. Mr. Weidong Yin has completed the required foreign exchange registration with respect to his investments in our company. However, we may not be aware of the identities of all of our beneficial owners who are PRC residents. We do not control our beneficial owners and cannot assure you that all of our PRC-resident beneficial owners will comply with SAFE Circular 37 and subsequent implementation rules. The failure of our beneficial owners who are PRC residents to register or amend their foreign exchange registrations in a timely manner pursuant to SAFE Circular 37 and subsequent implementation rules, or the failure of future beneficial owners of our company who are PRC residents to comply with the registration procedures set forth in SAFE Circular 37 and subsequent implementation rules, may subject such beneficial owners or our Chinese Mainland Subsidiaries to fines and legal sanctions. Furthermore, since it is unclear how any future regulation concerning offshore or cross-border transactions will be implemented by the relevant PRC government authorities, we cannot predict how these regulations will affect our business operations or future strategy. These risks may have a material adverse effect on our business, financial condition and results of operations.
- Regulation - Risk 14Restrictions on currency exchange may limit our ability to receive and use our revenues effectively.
In 2025, we received approximately 67.7% of our revenues in renminbi, which is not a freely convertible currency. A portion of these revenues may need to be converted into other currencies to meet our foreign currency obligations, including, among others, payment of dividends declared by Sinovac Antigua's subsidiaries. Under China's existing foreign exchange regulations, Sinovac Beijing, Sinovac LS, Sinovac Dalian and Sinovac Biomed are able to pay dividends in foreign currencies without prior approval from the State Administration of Foreign Exchange ("SAFE") by complying with certain procedural requirements. However, the PRC government may in the future restrict access to foreign currencies for current account transactions. Our Chinese Mainland Subsidiaries' ability to obtain foreign exchange is subject to significant foreign exchange controls and, in the case of amounts under the capital account, requires the approval of and/or registration with PRC government authorities, including SAFE. In particular, if we finance our Chinese Mainland Subsidiaries by means of foreign currency loans from the Company or other foreign lenders, the aggregate foreign debt may not exceed the difference between the approved total investment amount and the registered capital, each as approved by the Ministry of Commerce ("MOFCOM") and registered with SAFE. Such loans must also be registered with SAFE as foreign debts. If we finance our Chinese Mainland Subsidiaries by means of additional capital contributions from offshore, such contributions must first be approved by the relevant government authority. These limitations could affect the ability of our Chinese Mainland Subsidiaries to obtain foreign exchange through debt or equity financing.
- Regulation - Risk 15We may lose the right to use "??" (Kexing) on our vaccine products and/or as part of our trade name.
Since 2001, Sinovac Beijing has used "??" (Kexing) as part of its Chinese trade name. Sinovac Dalian has used "??" (Kexing) as part of its Chinese trade name since 2010. Shenzhen Kexing (an unrelated third party) registered the "??" trademark in China for Class 5 (Pharmaceuticals) under the International Classification of Goods and Services in 2001. To protect our interest in using "??" in our trade names, we applied to register the "??" trademark in China for Class 42 (Scientific & Technological Services & Research) in 2006, and our application was approved by the PRC Trademark Office in 2010. However, our registration in Class 42 does not directly address the risk posed by Shenzhen Kexing's prior registration in Class 5, the class under which our vaccine products fall. As of the date of this annual report, the "??" trademark owned by Shenzhen Kexing has not been recognized as a "Well-Known Trademark" (????) by the relevant PRC authorities. If, however, the "??" trademark owned by Shenzhen Kexing is recognized as a "Well-Known Trademark" in the future, which would afford it cross-class protection under PRC law, we may be subject to a trademark infringement claim for the use of "??" in our trade names. A successful trademark infringement claim could result in the loss of our ability to use "??" in our trade names, which could adversely affect our ability to maintain and protect our brands, cause us to incur significant litigation costs, and divert management attention and resources.
- Regulation - Risk 16We can only sell products that have received regulatory approvals. Many factors affect our ability to obtain such approvals.
Pre-clinical and clinical trials of our products, and the manufacturing and marketing of our products, are subject to extensive, costly and rigorous regulation by governmental authorities in the PRC and in other countries. Even if we complete pre-clinical and clinical trials successfully, we may not be able to obtain applicable regulatory approvals. We cannot market any product candidate until we have both completed our clinical trials and obtained the necessary regulatory approvals for that product candidate. Conducting clinical trials and obtaining regulatory approvals are uncertain, time-consuming and expensive processes. The process of obtaining required regulatory approvals from NMPA and other regulatory authorities often takes many years and can vary significantly based on the type, complexity and novelty of the product candidates. For example, it took us approximately ten years to develop and obtain regulatory approval to commercialize Healive, and it took us five and a half years and four and a half years to develop and obtain regulatory approvals to commercialize Bilive and Anflu, respectively. Our Inlive vaccine took us approximately eight years, from 2008 to 2016, to develop and obtain regulatory approval for commercialization. Delays in obtaining NMPA approvals for our products could result in substantial additional costs and adversely affect our ability to compete with other companies. Even if regulatory approval is ultimately granted, the approval may be subject to conditions, suspension, or withdrawal. Any approval received may also restrict the intended use and marketing of the applicable product candidate. There can be no assurance that all of the clinical trials for our vaccine candidates will be completed within the timeframes we currently anticipate. We could encounter difficulties in enrolling participants in clinical trials or encounter setbacks while conducting clinical trials that result in delays or cancellation. Data obtained from pre-clinical and clinical studies are subject to varying interpretations that could delay, limit or prevent regulatory approvals, and failure to comply with regulatory requirements or inadequate manufacturing processes could also prevent approvals. In addition, we may encounter delays or rejections in the event of additional regulation resulting from future legislation, administrative action or changes in the NMPA policy, or if unforeseen health risks arise among participants in clinical trials. Clinical trials may fail at any stage. Results of early-stage trials do not necessarily predict results of later-stage trials, and acceptable results in early-stage trials may not be replicated in later-stage trials. For these reasons, we do not know whether regulatory authorities will grant approval for any of our product candidates in the future. In addition, production permits for our products are valid for five years and we need to apply for renewal six months prior to their expiration. The process to approve our renewal applications could be lengthy and there is no assurance that we will be granted renewal in a timely manner or at all. Outside the PRC, our ability to market some of our products is contingent upon receiving marketing authorizations from the appropriate foreign regulatory authorities. For example, Healive can be supplied to certain international organizations and is eligible to participate in the tender process in some countries as it has passed the WHO prequalification assessment ("WHO PQ"). However, there are still countries that require additional marketing authorization for product sales notwithstanding WHO PQ status. These foreign regulatory approval processes include risks similar to those associated with the NMPA approval process as described above and may include additional risks.
- Regulation - Risk 17ChangedAs required by PRC laws, our Chinese Mainland Subsidiaries sell vaccines in China to CDCs, which are PRC government agencies. This exposes us to risks relating to doing business with the government.
As required by PRC laws, our Chinese Mainland Subsidiaries sell our vaccines to CDCs, which exposes us to various risks relating to doing business with the government. For example, demand for, and the ability to pay for, our products may be affected by government budgetary cycles, shifting availability of public funds, and changes in policy. Funding reductions, delays in payment, or unilateral demands for changes to the terms of our Chinese Mainland Subsidiaries' contracts by their government customers could adversely impact our results of operations and financial condition, exacerbate the existing seasonality of our revenues, and make it difficult for us to allocate resources or anticipate demand for our products. Furthermore, we have little or no control over government procurement decisions, and government agencies that contract to purchase our products may reduce or cancel orders, or demand price adjustments or other changes to their contracts with us, without our consent. Changes in the personnel of the PRC government agencies that purchase our products may result in changes to, delays in, or cancellations of purchase commitments due to, among other things, differing policy and budgetary agendas of the personnel involved. Similar changes could occur if a CDC or other relevant government agency were to be reorganized or consolidated with another government body. Any of the above-mentioned actions taken by government agencies could have a material adverse effect on our results of operations and expected earnings, or result in our failure to meet, or require downward adjustments to, our sales and gross margin guidance or estimates, which could adversely affect the Company's share price and result in substantial losses. In addition, many of the remedies that are available to us when dealing with private parties, such as claims for breach of contract or other legal remedies, may not be available or practicable in our dealings with government agencies.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.